Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications

Akiyode, Oluwaranti; Tran, Christine

doi:10.2337/diaspect.29.1.44

Cited by 4 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aflibercept is a soluble decoy receptor that binds VEGF-A, VEGF-B, and placental growth factor (PIGF) with a greater affinity than the body's native receptors. 5 Aflibercept is called a decoy receptor because VEGF does not bind to its original receptors and mistakenly binds with aflibercept, thereby reducing VEGF's activity. 5 Bevacizumab is a humanized monoclonal antibody that targets VEGF-A, an isoform of VEGF that stimulates endothelial cell proliferation and subsequent migration.…”

Section: Discussionmentioning

confidence: 99%

“… 5 Aflibercept is called a decoy receptor because VEGF does not bind to its original receptors and mistakenly binds with aflibercept, thereby reducing VEGF's activity. 5 Bevacizumab is a humanized monoclonal antibody that targets VEGF-A, an isoform of VEGF that stimulates endothelial cell proliferation and subsequent migration. 5 Aflibercept has the greatest binding affinity to VEGF receptors compared to ranibizumab and bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

“… 5 Bevacizumab is a humanized monoclonal antibody that targets VEGF-A, an isoform of VEGF that stimulates endothelial cell proliferation and subsequent migration. 5 Aflibercept has the greatest binding affinity to VEGF receptors compared to ranibizumab and bevacizumab. 5 After the induction period, bimonthly intravitreal aflibercept injection has been shown to be as safe and effective as ranibizumab monthly injection in the treatment of nAMD in phase III of VIEW 1 and VIEW 2 studies.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue

Davoudi

Roohipourmoallai

Guerin

et al. 2021

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose We describe a 61-year-old female patient with a retinal pigment epithelial detachment (PED) of the left eye in the setting of neovascular aged-macular degeneration (nAMD) with unanticipated responses to aflibercept and bevacizumab. Observations A reduction of PED size from 423 μm to 309 μm and vision improvement (20/150- to 20/40) were observed after five consecutive monthly injections of bevacizumab. A switch to aflibercept for the following two consecutive months showed an unanticipated incremental decline in vision (20/80- at month 1, 20/150- at month 2), increased PED size (749 μm), and the development of subretinal fluid (SRF). After a switch back to bevacizumab, the subretinal fluid resolved. After nine consecutive monthly injections of bevacizumab, final vision in the left eye was 20/25, and final PED height was 84 μm. Conclusions Different anti-VEGFs may induce varied and unpredictable responses among the most recalcitrant cases of nAMD. Unpredictably, PED size in our patient worsened with aflibercept treatment. Importance Treatment for nAMD with large PEDs has poor level 1 evidence for guidance, and customized treatment should be considered.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue

Davoudi

Roohipourmoallai

Guerin

et al. 2021

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

show abstract

“…Long-term hyperglycemia in diabetes will lead to various chronic complications in different tissues, such as chronic damage and dysfunction in the heart, blood vessels and eyes. Among them, cataract and retinopathy are the most common in eye complications of diabetes (19,20). Then, the quantitative expressions of TGF-β1 and MMP-9 between the two groups were compared at T1 and T2 after modeling.…”

Section: Discussionmentioning

confidence: 99%

Investigation of expression and effects of TGF‑β1 and MMP‑9 in lens epithelial cells of diabetic cataract rats

2019

Exp Ther Med

View full text Add to dashboard Cite

Expressions and effects of transforming growth factor- 1 (TGF-β1) and matrix metalloproteinase-9 (MMP-9) in lens epithelial cells (LECs) of diabetic cataract rats were investigated. A total of 40 female Sprague-Dawley rats were randomly divided into study and control group. Rats in study group were successfully modeled diabetic cataract rats, and rats in control group were normal rats. Immunohistochemical staining was used to determine positive and negative granules in cytoplasm, and image proplus image analysis system to calculate the integral optical density of the average positive area. Quantitative analysis was performed on TGF-β1 and MMP-9 in LECs of rats in study and control groups at the 2nd and 4th weekends. There were no statistically significant differences in length and age between the two groups of rats (P>0.05). Glucose concentration in the blood of rats in study group after modeling was significantly higher than that before modeling (P<0.001), and that after modeling was significantly higher in study group than that in control group (P<0.001). The expression of TGF-β1 protein in LECs of rats in study group at T2 (the 4th weekend) was significantly higher than that at T1 (the 2nd weekend) (P<0.001), and that of TGF-β1 protein was significantly higher in study group than that in control group at T1 and T2 (P<0.001). The expression of MMP-9 protein in LECs of rats in study group at T2 was significantly higher than that at T1 (P<0.001), and that of MMP-9 protein was significantly higher in study group than that in control group at T1 and T2 (P<0.001). The TGF-β1 expression was positively correlated with the MMP-9 expression in LECs of diabetic cataract rats (r=0.825, P<001). The increased expression of MMP-9 and TGF-β1 may play an important role in the occurrence and development of diabetic cataract.

show abstract

“…The growth of abnormal ocular blood vessels can be handled with anti-vascular endothelial growth factor (anti-VEGF) drugs [66]. Bevacizumab and ranibizumab, which are respectively full antibody and antibody fragment that bind VEGF-A, and aflibercept, a recombinant protein that traps VEGF-A and VEGF-B, are the cornerstones for the therapy of diabetes-related macular edema and retinopathy [67].…”

Section: Main Drug Classes and Current Administration Routesmentioning

confidence: 99%

Diabetic eye: associated diseases, drugs in clinic, and role of self-assembled carriers in topical treatment

Kattar

Concheiro

Alvarez‐Lorenzo

2021

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction: Diabetes is a pandemic disease that causes relevant ocular pathologies. Diabetic retinopathy, macular edema, cataracts, glaucoma, or keratopathy strongly impact the quality of life of the patients. In addition to glycemic control, intense research is devoted to finding more efficient ocular drugs and improved delivery systems that can overcome eye barriers. Areas covered: The aim of this review is to revisit first the role of diabetes in the development of chronic eye diseases. Then, commercially available drugs and new candidates in clinical trials are tackled together with the pros and cons of their administration routes. Subsequent sections deal with self-assembled drug carriers suitable for eye instillation combining patient-friendly administration with high ocular bioavailability. Performance of topically administered polymeric micelles, liposomes, and niosomes for the management of diabetic eye diseases is analyzed in the light of ex vivo and in vivo results and outcomes of clinical trials. Expert opinion: Self-assembled carriers are being shown useful for efficient delivery of not only a variety of small drugs but also macromolecules (e.g. antibodies) and genes. Successful design of drug carriers may offer alternatives to intraocular injections and improve the treatment of both anterior and posterior segments diabetic eye diseases.

show abstract

Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications

Cited by 4 publications

References 34 publications

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue

Exacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue

Investigation of expression and effects of TGF‑β1 and MMP‑9 in lens epithelial cells of diabetic cataract rats

Diabetic eye: associated diseases, drugs in clinic, and role of self-assembled carriers in topical treatment

Contact Info

Product

Resources

About